Sepsis, and related complications, is still a common cause of death in hospitalized patients worldwide, especially in critically ill neonates and children. Sepsis is also responsible for significant morbidity, and financial burden. It is very important to recognize sepsis early, since delayed diagnosis is associated with worse outcome. The early detection of sepsis remains a great challenge for clinicians because the use of blood cultures, the gold standard for diagnosis of bacteremia, is fraught with difficulties. The role of different immune and metabolic biomarkers is to improve the diagnosis, treatment and prognosis of sepsis. White blood cell count, C-reactive protein and procalcitonin are currently the most widely used biomarkers, but they have limited abilities to distinguish sepsis from other inflammatory conditions or to predict outcome. In this review, these biomarkers will be discussed along with novel diagnostic, prognostic and treatment response biomarkers, including interleukins -6, -8, -18, tumor necrosis factor -alpha, CD11b, CD64 and CD15s. The future of sepsis biomarkers lies in extensive validation studies of all novel biomarkers and their combinations as early predictors of sepsis. Also, research to identify novel sepsis biomarkers and develop specific therapeutic strategies based on biomarker information has to be continued.
Introduction
Serious bacterial infections (SBI) are among the leading causes of morbidity and mortality in children worldwide, with a reported rate in young febrile infants between 8.5% and 12%. (1) (2) (3) Sepsis, a diagnosis established according to criteria defined by Levy et al. (4) , including documented or suspected infection and findings of inflammation such as hemodynamic instability, tissue perfusion alteration and indications of organ dysfunction, is a leading cause of death in critically ill patients despite the use of broad spectrum antibiotics and modern resuscitation therapies. (5) Besides sepsis, the SBI group includes microbiologically confirmed bacteraemia, bacterial meningitis, urinary tract infection, pneumonia confirmed by an infiltrate on chest x ray, bacterial gastroenteritis, or cellulitis. (6) Early recognition of SBI is associated with better treatment outcome. (7) Unfortunately, diagnosis of bacterial infections is sometimes challenging, because the use of blood culture, the gold standard for diagnosis of bacteremia, is fraught with difficulties.
First, incubation of bacteria may take several days (2-4 days) . Second, genuine bacteremia may remain undetected in a large proportion of infected cases because of the small volume of blood taken. Third, bacteremia in the neonate may often be transient or intermittent, especially during the early stages of infection. (8) All of this has led to the investigation of various other biomarkers. Biomarkers are extremely important in the process of diagnosis of sepsis and evaluation of its severity because they can indicate the presence or absence or severity of sepsis, (9) and can help differentiate bacterial from viral and/or fungal infection. It remains difficult to differentiate sepsis from other noninfectious causes of systemic inflammatory response syndrome, and there is continuous search for better biomarkers of sepsis.
Based on the National Institutes of Health consensus conference in 2001, (10) a biomarker is defined as a characteristic that can be measured objectively and evaluated as an indicator of normal biological processes, pathologic processes, or pharmacologic responses to a therapeutic intervention. There are four major types of biomarkers: diagnostic, monitoring, stratification and surrogate biomarkers. (9, 11) Diagnostic biomarkers serve to identify the presence or absence of a disease or other clinical condition. The majority of diagnostic biomarkers are of most value within a specific clinical context since it is very rare that a diagnostic biomarker is strictly present or absent. The presence of a biomarker is measured and cut-offs are defined to establish the presence or absence of disease. This class includes the subset of screening biomarkers. Monitoring biomarkers are molecules or proteins whose levels change dynamically as a disease process evolves or in response to applied therapeutic interventions. Valuable monitoring biomarkers must, therefore, be functionally or biologically linked to the mechanism of action of a given therapeutic intervention. Stratification biomarkers are useful to sort a population of patients into different classes of severity. An effective and useful stratification biomarker can identify higher risk patients who would benefit from more toxic, more aggressive, or higher risk therapies. Finally, surrogate biomarkers are used to predict outcome of a disease process rather than follow its course or to titrate therapy.
They serve as proxy end points for severe or rare patient-centered outcomes such as death or significant complications.
In order to be clinically useful, a biomarker should have a well-defined cut-off value to differentiate infected from non infected patients, and it should be able to do that at an early stage of disease. For diagnostic purposes, a very high sensitivity and negative predictive value (approaching 100%) and good specificity and positive predictive value (>85%) are desirable. (8) However, if the diagnostic marker is unable to satisfy the above criteria, then the optimal cut-off could be chosen so that both the sensitivity and the specificity approach 80%. Second, the kinetics of a biomarker should be considered because a rapid increase of its value would allow a good discrimination between health and disease.
Third, with reference to the laboratory characteristics, the infection biomarker should be biochemically stable because it might be necessary to keep blood samples stored.
A set of different tests including the white blood cell (WBC) count, leukocyte differential counting for evidence of a myeloid left shift, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin (PCT), and microbiologic cultures is used in the laboratory evaluation of patients with suspected infection or sepsis. Also, many different clinical scores have been developed to detect patients at high or low risk of sepsis or other SBI. However, none of the evaluated clinical scales and laboratory markers have been shown to be sensitive or specific enough to be used as a tool to determine the absence or presence of SBI in neonates and children with absolutely no doubt. Therefore, the new generation of biomarkers and improved diagnostics for infection have been directed towards soluble biomarkers in the serum or plasma, and towards analysis of leukocyte cell surface molecules. (12, 13) White blood cells (WBC) count is the most commonly used biomarker in clinical practice and diagnostic algorithms commonly used to evaluate neonates, infants or children with fever include the interpretation of WBC. Among febrile children a WBC of < 5 or ≥ 15 x 10 9 /l is considered to be associated with an increased risk of SBI.
However, some studies have indicated that WBC is not a reliable nor accurate indicator of SBI in febrile infants. In 2001, Galletto-Lacour et al. (14) confirmed that total and differential leukocyte count performed poorly compared to PCT and CRP. WBC cut-off of 15 x 10 9 /l had a sensitivity of 68% and specificity of 77%. Band count > 1.5 x 10 9 /l sensitivity was 29%, and specificity 91%. (14) Bonsu et al. (15) found that use of the WBC cut-off of 15 x 10 9 /l would have yielded a sensitivity of only 45% and specificity of 78%. Even the use of a lower cut-off of 5 x 10 9 /l would not detect 21% patients with bacteremia. Similar results were presented by the study done by Galletto-Lacour in 2003. (16) They showed that WBC cut-off of 15 x 10 9 /l had a poor sensitivity of 52% and specificity of 74%. The value of band count was even worse and extremely poor, with sensitivity of only 11% (16) . Rudinsky et al. (17) also found that the suggested cut-offs of a WBC count < 5 x 10 9 /l and > 15 x 10 9 /l were not accurate and reliable predictor of SBI in infants age 3 to 24 months since no statistical difference was detected in the WBC count between the SBI and non-SBI groups.
C reactive protein (CRP)
is an acute-phase reactant synthesized by the liver in response to elevated levels of the proinflammatory cytokines (IL-1, IL-6 and TNF-α). It is produced within 4-6 hours after onset of tissue injury or inflammation, and it doubles every 8 hours before peaking around 36 hours. (18) CRP is frequently used as part of the assessment of children with fever of unknown origin, however, its levels become elevated in any disease process with tissue injury, not just infection. CRP is also among the most widely used biomarkers in neonates. (19) Franz et al. considered a CRP value >10 mg/L, in the presence of one (or more) clinical sign(s) compatible with infection, as a criterion to make a diagnosis of clinical septicemia in neonates. (20) However, due to the time lag in the response of CRP to infection, some clinicians use it in combination with other biomarkers. Pulliam et al. (21) reported the results of a prospective study in 2001 examining the utility of CRP in evaluating febrile children. Seventy-seven children 1 to 36 months of age were enrolled in this study. CRP was found to be a much more useful biomarker than WBC count for this group of patients, with sensitivity of 79% and specificity of 91%. Galetto-Lacour et al. (14) also evaluated the utility of CRP as a potential biomarker of infection.
Children were prospectively enrolled at a pediatric emergency department in a European university hospital. A CRP cutoff of 40 mg/l resulted in a sensitivity of 89% and specificity of 75%; more sensitive than Pulliam et al., (21) but also less specific. Similar results were found by Galetto-Lacour two years later in a follow-up study, (16) which showed that CRP levels were superior to WBC counts in detecting SBIs, with reported sensitivity and specificity of 79%. The study by Olaciregui et al., (6) focused on infants aged ≤3 months, also showed that CRP appears to be useful in predicting SBI and recommended that it should be used in combination with other markers for management of febrile patients in this age group. Other authors, (3) studying the same age group, similarly reported that various cut-offs of CRP had a better sensitivity and specificity than WBC cut-offs. Nevertheless, despite the high specificity of CRP, its sensitivity was low.
Procalcitonin (PCT)
is a 116-aminoacid peptide and also an acutephase reactant. PCT level begins to rise 4 hours after exposure to bacterial endotoxin, peaks at 6-8 hours, and remains elevated for at least 24 hours. (22) It has been used to diagnose the severity of systemic inflammatory response, to determine the progression of infection to sepsis and septic shock, to assess responsiveness to treatment, and to estimate prognosis. (22) Increases in PCT occur before, and more rapidly, than increases in CRP and its peak level is achieved sooner. Additionally, when the patient responds appropriately to therapy, PCT levels decrease to normal much quicker than those of CRP. The most important clinical applicability of PCT as a biomarker may be in determining the initiation (diagnostic biomarker) and duration (monitoring biomarker) of antibiotic therapy. (11) All studies on severe, invasive bacterial infections in children report higher sensitivities and specificities of PCT than for CRP, (23) (24) (25) although its value has also been challenged. (22) In 2003, published the results of their prospective research confirming the superiority of PCT. One hundred and ten febrile children aged 7 days to 36 months presenting to a pediatric emergency department were enrolled. A PCT cutoff of 0.5 ng/ml resulted in a sensitivity of 93% and specificity of 74%, similar to the author's previous findings. CRP was less sensitive and specific: the proposed optimum cutoff of 40 mg/L was 52% sensitive and 74% specific. The large study on PCT was that of Gendrel et al. (26) The authors, in a group of children hospitalized after admission to the Emergency Department, found that PCT, at the cut-off of 2 ng/mL, had a very high sensitivity (96%) and specificity (87%) in detecting invasive bacterial infection and performed much better than CRP at different cut-offs. Similar results were reported by Fernandez Lopez et al. (23) Four hundred and forty-five children were enrolled. Eighty children were diagnosed with "localized" bacterial infections while 150 patients were diagnosed with "invasive" bacterial infections (sepsis, pyelonephritis, meningitis, and lobar pneumonia). The authors found PCT to be the best predictor of bacterial infection. Using a calculated optimum cut-off of 0.53 ng/ml, the authors reported sensitivity of 65.5%, and specificity of 94.3%. CRP (> 27.5 mg/L) was less sensitive (63.5%) and less specific (84.2%). When used to differentiate only those children who were diagnosed with invasive bacterial disease, PCT ≥ 0.59 ng/ml had a sensitivity of 91.3% and specificity of 93.5%, much better than the 78% and 75% noted with CRP, respectively. In this study, both PCT and CRP were found to perform better when compared to WBC and ANC in detecting invasive infections.
Cytokines
Sepsis is a syndrome characterized by a systemic inflammatory response in which the cytokines produced by immune cells, in response to bacterial products, are important mediators. Increased plasma levels of cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 and IL-6 have been found in sepsis, and a significant correlation between high levels of these cytokines and poor clinical outcome has been reported. (27, 28) The initial cytokinaemia is accompanied by a compensatory response of raised concentrations of circulating anti-inflammatory cytokines (eg, interleukin 10) Interleukin 6 (IL6) is an interesting biomarker for clinicians since its levels appear to rise several hours prior to elevation of CRP in the face of infection, and it was found more useful than IL-1 or TNF-alpha in predicting bacteremia in children. (29) determined in their population of neonates that IL-18 had no diagnostic ability. (36) Therefore, the utility of IL-18 as a diagnostic biomarker for sepsis remains to be further evaluated, and much more study, especially in the pediatric population, is needed to clarify the utility of this biomarker in the diagnosis of sepsis.
Tumor necrosis factoralpha (TNFalpha) is another biomarker whose plasma levels were found significantly increased in the group of neonates with proven sepsis compared to the control group of patients. In that study, the sensitivity and specificity of TNF-alpha for the diagnosis of neonatal sepsis were 60% and 84%, respectively. (30) TNF-alpha is also a sensitive marker and has a high sensitivity and negative predictive value for detecting late onset infection in very low birth weight (VLBW) newborns. (37) In contrast, IL1β and Eselectin had rather low sensitivity for detecting late onset infection within the first 48 hours in VLBW. In the same article it was shown that the use of multiple markers (IL-6, TNF-alpha and CRP) in combination, was associated with higher sensitivity and better negative predictive values. In particular, the use of CRP with either IL-6 or TNF-alpha seemed to be most sensitive for confirming infection. After calculating all possible combinations and permutations for these three tests within the first 48 hours of infection, CRP and IL-6 on day 0 combined with either TNF-alpha on day 1 or CRP on day 2 provided the best overall sensitivity (98%) and specificity (91%) for the diagnosis of late onset infection. (37) Leukocyte cell surface molecules integrins have a common β-subunit (β2, CD18) and distinct α-subunits (CD11a, CD11b, CD11c, and CD11d). On the neutrophil surface, L-selectin (CD62L) interacts with specific oligosaccharide moieties on endothelialcell surface glycoproteins, whereas on the endothelium, E-selectin (CD62E) and P-selectin (CD62P) similarly recognize specific neutrophil carbohydrate motifs. Transient rolling helps neutrophils to make contact with inflammatory factors that are expressed on the endothelial surface.
This interaction stimulates the neutrophils to rapidly increase the avidity of the β2 integrins for the endothelial ligand. The integrin CD11b/CD18 (complement receptor type 3 [CR3], Mac-1, or αMβ2) is the predominant β2 integrin in neutrophils. In resting non-stimulated neutrophils from adults, 95% of the total cell content of CD11b/CD18 complexes occurs as membrane components of specific granules and secretory vesicles, i.e., in intracellular storage granules, with only 5% of the complexes expressed on the cell surface. (39) The expression of CD11b on neutrophils in sepsis has been reported to be increased and serves as an activation marker of neutrophils, may predict the development of organ failure in patients with septic shock (31) and is indicative of a poor prognosis. (40) The Turunen et al. study shows that determination of CD11b expression may be useful in early identification of ELBW infants with late-onset sepsis. (41) The results of this study demonstrated that CD11b expression has increased in some infants from the infection group up to 3 days before the onset of symptoms suggesting that CD11b measurements may enable, at least in some infants, early diagnosis of infection. It has been also found that an increase in neutrophil surface density of CD11b/CD18 is a promising and Fcγ receptor I (FcγRI), which is the high affinity receptor for monomeric IgG1 and IgG3, is recognized by the monoclonal antibody CD64. (48) It has a molecular weight of 72 kDa and it encoded by three genes on the long arm of chromosome 1. CD64 is expressed only to a very low extent on resting neutrophils, (12) and is considered to be a marker of activated neutrophils. The quantification of CD64 expression on the surface of neutrophils by flow cytometry has been proposed as a diagnostic test for sepsis in neonates, (30, 49, 50) 
Other biomarkers
A number of acute phase proteins including alpha1-antitrypsin, fibronectin, haptoglobin, lactoferrin, neopterin, inter-a inhibitor proteins, granulocyte colony stimulating factor, orosomucoid, and antithrombin have been evaluated in relation to neonatal sepsis.
Although these acute phase proteins may be candidate biomarkers for sepsis, none has been routinely used clinically or studied on a large scale.
Serum amyloid A (SAA) is an acute phase protein induced by the proinflammatory cytokines. There is a significant increase in SAA levels from 8 to 24 h after the onset of sepsis and it was shown that SAA had 
Conclusion
In conclusion, it is evident that, to date, none of the above mentioned biomarkers alone or in combination are 100% sensitive and specific, allowing neonatologists or pediatricians to withhold antibiotic treatment in an infant or older child with clinical signs suggestive of infection.
Furthermore, analysis of some biomarkers in the clinical setting, like cell surface markers, requires specialized equipment and qualified personnel readily available. This limits the practical application of this technology. Therefore, the search for better biomarkers continues…
